Autolus Therapeutics vs Arcus Biosciences
Arcus Biosciences is the larger business, with $247m of revenue in fiscal 2025 against $75.4m for Autolus Therapeutics (3.3 times as much). Autolus Therapeutics grew faster (644.9% against -4.3%). Arcus Biosciences kept more of each dollar of sales as profit: a net margin of -142.9% against -381.4%. Autolus Therapeutics carries less debt relative to equity (0.0% against 15.8%).
| Latest fiscal year | Autolus TherapeuticsAUTL, 2025 | Arcus BiosciencesRCUS, 2025 |
|---|---|---|
| Revenue | $75.4m | $247m |
| Revenue growth | 644.9% | -4.3% |
| Net income | −$288m | −$353m |
| Operating margin | -358.9% | -156.3% |
| Net margin | -381.4% | -142.9% |
| Return on equity | -95.0% | -63.3% |
| Free cash flow | −$303m | −$484m |
| Cash | $104m | $222m |
| Total debt | $0 | $100m |
| Debt to equity | 0.0% | 15.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 754 | 601 |
| Market value | $371m | $2.39bn |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 0 sales |